[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,850,724
  • Shares Outstanding, K 147,637
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,420 M
  • EBITDA $ 3,493 M
  • 60-Month Beta 0.16
  • Price/Sales 2.99
  • Price/Cash Flow 8.86
  • Price/Book 1.59

Options Overview Details

View History
  • Implied Volatility 42.09% (-0.10%)
  • Historical Volatility 47.34%
  • IV Percentile 85%
  • IV Rank 62.41%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 5) 5.10 (2.52%)
  • Put/Call Vol Ratio 0.87
  • Today's Volume 774
  • Volume Avg (30-Day) 1,965
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 42,618
  • Open Int (30-Day) 51,801
  • Expected Range 197.09 to 207.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.98
  • Number of Estimates 11
  • High Estimate $4.21
  • Low Estimate $-21.10
  • Prior Year $5.47
  • Growth Rate Est. (year over year) -82.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
186.02 +8.69%
on 07/15/26
219.72 -7.98%
on 06/29/26
+2.60 (+1.30%)
since 06/24/26
3-Month
179.15 +12.86%
on 04/27/26
219.72 -7.98%
on 06/29/26
+17.81 (+9.66%)
since 04/24/26
52-Week
124.56 +62.33%
on 08/01/25
219.72 -7.98%
on 06/29/26
+69.60 (+52.49%)
since 07/24/25

Most Recent Stories

More News
3 Profitable Stocks We Steer Clear Of

3 Profitable Stocks We Steer Clear Of

RVLV : 24.99 (+2.33%)
OCSL : 11.68 (+0.52%)
BIIB : 202.19 (+0.78%)
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide.

BIIB : 202.19 (+0.78%)
Biogen Appoints Michael J. Parini as Chief Legal Officer

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve...

BIIB : 202.19 (+0.78%)
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

BIIB : 202.19 (+0.78%)
Stocks Settle Higher on Tame Inflation News

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.38%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.10%. September E-mini...

SNDK : 1,436.56 (-10.79%)
HL : 15.14 (-1.17%)
CDE : 15.13 (-0.72%)
TRI : 90.15 (+5.20%)
STX : 851.69 (-6.75%)
AMD : 521.95 (-3.29%)
SCCO : 179.29 (-1.61%)
SPY : 738.93 (+0.10%)
ADSK : 209.75 (+2.19%)
MU : 920.95 (-6.99%)
ORCL : 114.99 (-4.21%)
QQQ : 684.23 (-1.12%)
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting

BIIB : 202.19 (+0.78%)
An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

DNLI : 23.11 (-1.32%)
IONS : 56.55 (+1.22%)
NAMS : 29.64 (-2.98%)
BIIB : 202.19 (+0.78%)
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Clinical outcomes : Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest...

BIIB : 202.19 (+0.78%)
1 Mid-Cap Stock to Target This Week and 2 We Find Risky

1 Mid-Cap Stock to Target This Week and 2 We Find Risky

AFG : 143.76 (+1.84%)
DXCM : 71.54 (+1.50%)
BIIB : 202.19 (+0.78%)
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.)

BIIB : 202.19 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 206.91
2nd Resistance Point 205.11
1st Resistance Point 203.65
Last Price 202.19
1st Support Level 200.38
2nd Support Level 198.58
3rd Support Level 197.12

See More

52-Week High 219.72
Last Price 202.19
Fibonacci 61.8% 183.37
Fibonacci 50% 172.14
Fibonacci 38.2% 160.91
52-Week Low 124.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.